Patents by Inventor Wolfgang PRANGE

Wolfgang PRANGE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRANSDERMAL ADMINISTRATION OF MEMANTINE
    Publication number: 20190298662
    Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 3, 2019
    Inventors: René EIFLER, Michael HORSTMANN, Regine KAUFMANN, Patrick MOHR, Eric GALIA, Wolfgang PRANGE, Stefan BULLER, Klaus PUSECKER, Jan STAMPFUSS, Susanne STOELBEN
  • Transdermal administration of memantine
    Patent number: 10363228
    Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: July 30, 2019
    Assignees: LTS Lohmann Therapie-Systeme AG, Gruenenthal GmbH
    Inventors: René Eifler, Michael Horstmann, Regine Kaufmann, Patrick Mohr, Eric Galia, Wolfgang Prange, Stefan Buller, Klaus Pusecker, Jan Stampfuss, Susanne Stoelben
  • MULTIPARTICULATE ORAL DOSAGE FORM PROVIDING PROLONGED RELEASE OF TAPENTADOL
    Publication number: 20180369151
    Abstract: The invention relates to an oral pharmaceutical dosage form comprising a plurality of coated particles, wherein said coated particles comprise a core which comprises a Tapentadol component and which is coated with a controlled release coating material, wherein the controlled release coating material comprises a lubricant component and a polymer component, wherein the polymer component comprises one or more cellulose ethers and/or one or more acrylates, and wherein the pharmaceutical dosage form provides controlled release of the Tapentadol component.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 27, 2018
    Applicant: GRÜNENTHAL GMBH
    Inventors: Marc SCHILLER, Ulrich REINHOLD, Ulrike BERTRAM, Wolfgang PRANGE, Anika-Anina PHILIPP, Stefanie STRAUB, Annette GRAVE, Norbert POELLINGER